These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27974669)

  • 1. Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex Percutaneous Coronary Intervention With Early Discontinuation of Dual-Antiplatelet Therapy.
    Noad RL; Hanratty CG; Walsh SJ
    J Invasive Cardiol; 2017 Feb; 29(2):36-41. PubMed ID: 27974669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multicenter IDEAL-LM trial.
    Lemmert ME; Oldroyd K; Barragan P; Lesiak M; Byrne RA; Merkulov E; Daemen J; Onuma Y; Witberg K; van Geuns RJ
    Am Heart J; 2017 May; 187():104-111. PubMed ID: 28454794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial.
    Natsuaki M; Morimoto T; Yamamoto E; Shiomi H; Furukawa Y; Abe M; Nakao K; Ishikawa T; Kawai K; Yunoki K; Shimizu S; Akao M; Miki S; Yamamoto M; Okada H; Hoshino K; Kadota K; Morino Y; Igarashi K; Tanabe K; Kozuma K; Kimura T
    Cardiovasc Interv Ther; 2016 Jul; 31(3):196-209. PubMed ID: 26518420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
    Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
    Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention.
    Mauri L; Kirtane AJ; Windecker S; Yeh RW; Dauerman HL; Price MJ; Christen T; Allocco DJ; Meredith IT; Kereiakes DJ
    Am Heart J; 2018 Nov; 205():110-117. PubMed ID: 30218844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
    Kereiakes DJ; Meredith IT; Windecker S; Lee Jobe R; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Christen T; Allocco DJ; Dawkins KD
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25855680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
    Vesga B; Hernandez H; Moncada M; Gasior P; Higuera S; Dager A; Arana C; Delgado JA; Généreux P; Maehara A; Granada JF
    Coron Artery Dis; 2017 Mar; 28(2):126-134. PubMed ID: 27879518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
    Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
    Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stent Thrombosis and Dual Antiplatelet Therapy Interruption With Everolimus-Eluting Stents: Insights From the Xience V Coronary Stent System Trials.
    Généreux P; Rutledge DR; Palmerini T; Caixeta A; Kedhi E; Hermiller JB; Wang J; Krucoff MW; Jones-McMeans J; Sudhir K; Simonton CA; Serruys PW; Stone GW
    Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25940520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impact of abluminal groove-filled biodegradable-polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent on and off dual antiplatelet therapy.
    Saito Y; Wijns W; Baumbach A; Xu B; Kelbaek H; Zheng M; Morel MA; Anderson R; Schächinger V; Lansky A;
    Catheter Cardiovasc Interv; 2022 Feb; 99(2):357-365. PubMed ID: 33502809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial.
    Min PK; Kang TS; Cho YH; Cheong SS; Kim BK; Kwon SW; Park WJ; Lee JH; Kim W; Lee WS; Yoon YW; Lee BK; Kwon HM; Hong BK;
    JAMA Netw Open; 2024 Mar; 7(3):e240877. PubMed ID: 38451525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-Year Outcomes of Multivessel Percutaneous Coronary Intervention With Xience V Everolimus-Eluting Stents.
    Lee MS; Shlofmitz R; Mahmud E; Park KW; Rha SW; Gaborro A; Wang J; Zhao W; Sudhir K
    J Invasive Cardiol; 2019 Sep; 31(9):240-246. PubMed ID: 31478889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Olivecrona G; Varenhorst C; Danielewicz M; Hambraeus K; Lindholm D; Råmunddal T; Witt N; James S
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):881-887. PubMed ID: 28544146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
    Smits PC; Vlachojannis GJ; McFadden EP; Royaards KJ; Wassing J; Joesoef KS; van Mieghem C; van de Ent M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1157-1165. PubMed ID: 26210806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.